BVS

DURHAM, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, Bioventus Senior Vice-President and Chief Financial Officer, will participate in a fireside chat at the Goldman Sachs Global

Q1 reported revenue of $132.1 million increased 7% First quarter GAAP earnings of $0.04 per diluted share compared to the prior-year period loss of $0.04 per diluted share Non-GAAP earnings* of $0.15 per diluted share compared to $0.08 per diluted share in the prior-year period Cash from operations

DURHAM, N.C., April 28, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2026 before the market opens on Wednesday, May

Q4 reported revenue of $157.9 million increased 2.8% and organic* revenue increased 10.0% Fourth quarter GAAP earnings of $0.21 per diluted share compared to $0.00 in the prior-year period Non-GAAP earnings* of $0.24 per diluted share Fourth quarter cash from operations of $38.0 million increased

DURHAM, N.C., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal year 2025 before the market opens on Thursday, March

DURHAM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, Chief Executive Officer, will present at the 44 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 9:45

DURHAM, N.C., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, Bioventus President and Chief Executive Officer, will present at the Piper Sandler Healthcare Conference on Wednesday, December 3,

Q3 reported revenue of $138.7 million was comparable to last year and organic* revenue advanced 8% Third quarter GAAP earnings of $0.05 per diluted share increased compared to the prior-year period loss of $0.08 per diluted share Non-GAAP earnings* of $0.15 per diluted share increased 200% Cash

DURHAM, N.C., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the third quarter of fiscal year 2025 before the market opens on Tuesday,

DURHAM, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, Bioventus Senior Vice-President and Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley Global